Hormonal cycle changes how much davunetide reaches the brain

A new study found that the brain-protecting drug davunetide reached female mouse brains in much higher amounts when estrogen was high, and a small human dataset pointed in the same direction. The findings suggest sex and hormonal state could help explain why some neuroprotective drugs look ineffective on average. Why it matters: - The study suggests drug exposure in the brain can shift with sex and hormonal cycle, not just dose. - That could help explain why clinical trials sometimes miss benefits that may exist in subgroups. - The findings are especially relevant to tau-related brain disorders, including Alzheimer’s disease, where women are affected at higher rates. What happened: - Researchers studied intranasal davunetide, also known as NAP, in female and male mice and in a small human pharmacokinetic dataset. - The work was published June 16, 2026, in Genomic Psychiatry. - The mouse experiments used fluorescent tagging and live imaging to track how the drug moved into the body and head. - The human dataset came from an earlier intranasal davunetide study in healthy adults, including two men and six women. The details: - In female mice, the drug reached the head in higher amounts when estrogen was highest. - During proestrus and estrus, female mice showed significantly more head uptake than males. - The strongest difference appeared in proestrus, with a head measurement p-value of 0.00029 and a head-to-body ratio p-value of 0.000004. - The sex difference faded during metestrus, when estrogen falls. - In a mixed group of five males and five females imaged without cycle sorting, females still showed higher head uptake at every time point. - That mixed-group analysis showed a significantly higher head-to-body ratio in females, with a p-value of 0.000009. - In the human data, women trended toward higher peak concentrations of davunetide. - The highest female peak was more than double the highest male peak. - Men retained the drug longer, and the longer half-life across the first two days was significant, with a p-value of 0.0057. - The higher female peak concentration remained a trend, with a p-value of 0.1081. - The authors said the sex-specific differences likely reflect a mix of hormonal regulation, tissue distribution, nasal physiology and blood-brain barrier function. - The study also reported increased male vulnerability in elderly mouse experiments, with male mice dying during the procedure. Between the lines: - The study points to biology that trial averages can hide. - If brain drug delivery changes with hormonal state, a treatment can look ineffective in a mixed group while still working in a subset. - The findings also fit a broader pattern in which estrogen influences blood-brain barrier integrity and related transport processes. - The authors also note that ADNP, the protein related to davunetide, is regulated by the estrous cycle and helps regulate sex hormones. - The paper is careful not to overstate the result: davunetide remains investigational, the mouse group sizes were small, and the human sample was tiny. - The estrous staging in mice relied on microscope review of vaginal smears. What’s next: - The results strengthen the case for including biological sex and hormonal state in neuroprotective drug research. - Larger human studies would be needed to test whether the mouse pattern holds in women across the menstrual cycle. - The findings could influence how future trials dose and analyze drugs aimed at the brain. The bottom line: - The same intranasal brain drug may not reach the brain the same way in every person, or even in the same woman across her cycle.